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Abstract
Subcortical small vessel disease (SVD) is characterized by white matter damage resulting
from arteriolosclerosis and chronic hypoperfusion. Transforming growth factor beta 1
(TGFB1) is dysregulated in the hereditary SVD, CARASIL (cerebral autosomal recessive
arteriopathy with subcortical infarcts and leukoencephalopathy). However, very little is
known about the role of the largest group in the TGFB superfamily – the bone
morphogenetic proteins (BMPs) – in SVD pathogenesis. The aim of this study was to
characterize signaling abnormalities of BMPs in sporadic SVD. We examined
immunostaining of TGFB1 and BMPs (BMP2/BMP4/BMP6/BMP7/BMP9) in a total of 19
post-mortem human brain samples as follows: 7 SVD patients (4 males, 76–90 years old); 6
Alzheimer’s disease (AD) patients (2 males, 67–93 years old) and 6 age-matched disease
controls (3 males, 68–78 years old). We subsequently investigated the effects of oxygen–
glucose deprivation and BMP4 addition on cultured cells. Furthermore, adult mice were
subjected to chronic cerebral hypoperfusion using bilateral common carotid artery stenosis,
followed by continuous intracerebroventricular infusion of the BMP antagonist, noggin. In
the SVD cases, BMP4 was highly expressed in white matter pericytes. Oxygen–glucose
deprivation induced BMP4 expression in cultured pericytes in vitro. Recombinant BMP4
increased the number of cultured endothelial cells and pericytes and converted
oligodendrocyte precursor cells into astrocytes. Chronic cerebral hypoperfusion in vivo also
upregulated BMP4 with concomitant white matter astrogliogenesis and reduced
oligodendrocyte lineage cells, both of which were suppressed by intracerebroventricular
noggin infusion. Our findings suggest ischemic white matter damage evolves in parallel with
BMP4 upregulation in pericytes. BMP4 promotes angiogenesis, but induces astrogliogenesis
at the expense of oligodendrocyte precursor cell proliferation and maturation, thereby
aggravating white matter damage. This may explain white matter vulnerability to chronic
hypoperfusion. The regulation of BMP4 signaling is a potential therapeutic strategy for
treating SVD.
INTRODUCTION
Vascular cognitive impairment develops as a consequence of vari-
ous types of cerebrovascular alterations. Subcortical white matter
changes caused by small vessel alterations are frequently observed
in vascular cognitive impairment and are referred to as subcortical
‘small vessel disease (SVD)’ (39). Disturbances in cerebrospinal
fluid production (40), cerebral edema (22), breakdown of the
blood–brain barrier and increased permeability (21, 54), oxidative
stress (4), and inflammation have been cited as important causes in
the development of white matter changes (19). However, the exact
mechanisms have yet to be fully elucidated. Recent studies have
noted that attenuations of vasculature and white matter are also fre-
quently observed in other neurodegenerative disorders, especially
in Alzheimer’s disease (AD) (46, 59). However, vascular risk fac-
tors are related to a lesser degree to a pure type of AD (10, 38) or
mixed type (AD with vascular pathology) dementia (23) compared
with vascular cognitive impairment. The involvement of different
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etiologies has been suggested in white matter damage between
SVD and AD (13, 20). Therefore, clarification of causative factors
that underlie various forms of white matter changes should enable
the development of novel strategies for tackling cognitive
impairment.
There are several recognized forms of inherited SVD (9), includ-
ing CARASIL (cerebral autosomal recessive hereditary cerebral
artery disease and arteriosclerosis with subcortical infarcts and leu-
koencephalopathy). The gene responsible for CARASIL is HTRA1
(high-temperature requirement A 1), and the resultant upregulation
of transforming growth factor beta (TGFB) family signaling is
postulated to underlie the small vessel changes observed in CARA-
SIL (18). The TGFB superfamily also includes the bone morphoge-
netic protein (BMP) family proteins.
BMPs are involved in oligovascular pathologies in the ischemic
brain, in addition to their physiological roles in embryonic and
bone tissues. In an ischemic intrauterine growth retardation model,
oxidative stress upregulates BMP4 and mediates periventricular
white matter injury with a paucity of mature oligodendrocytes and
hypomyelination, while BMP deletion reverses these defects (36).
In neonatal mouse brains, BMP4 expression increases as a conse-
quence of global hypoxia-ischemia, while the BMP antagonist nog-
gin protects the white matter against damage (12). Furthermore, in
adult mouse brains with focal cerebral ischemia, overexpressed
noggin reduces infarct volume and motor deficits (44). These
experimental results highlight the potential of BMP antagonism in
the treatment of ischemic demyelinating disorders.
Nevertheless, the exact role of BMP family members remains
poorly understood in the context of chronic hypoperfusion in the
adult human brain. Therefore, the present study explored the under-
lying etiology of white matter abnormalities, specifically focusing
on BMP expression through the use of postmortem human brains,
cultured cells exposed to oxygen–glucose deprivation (OGD), and
chronic hypoperfusion mouse brains.
MATERIALS AND METHODS
Experimental design of postmortem brain
material
Study samples were selected from 371 autopsied brains retained at
Kyoto University Hospital from 1983 to 2009. This collection was
approved by the institutional research committee, Kyoto University
Graduate School and Faculty of Medicine, Ethics Committee. Neu-
ropathological diagnoses were made according to thorough histo-
pathological examination of extensively sampled brain sections, as
previously described (1, 35). Cases with mixed SVD and AD path-
ological diagnoses were excluded to select for brain samples with
relatively single processes. We analyzed a total of 19 postmortem
brain samples as follows: 7 SVD patients (4 males, 76–90 years
old, brain weight 11016 89.9 g); 6 AD patients (2 males, 67–93
years old, brain weight 10566 67.7 g) and 6 age-matched disease
controls (3 males, 68–78 years old, brain weight 11906 113.7 g).
Table 1 provides demographics and pathological features of the 19
subjects. The clinical diagnosis of dementia met the criteria of the
Diagnostic and Statistical Manual of Mental Disorders IV (2). The
AD neuropathological diagnoses were made according to the pres-
ence of frequent senile plaques in the neocortex (32), and no less
than stage V of Braak stage of neurofibrillary tangles (6, 7). The
diagnosis of SVD, or subcortical ischemic vascular dementia was
clinically made (5) and was retrospectively found to meet the path-
ological criteria outlined by Kalaria et al (24). Two observers
(M.T.U. and M.I.) individually assessed senile plaque and
Table 1. Demographics of subjects and pathological analysis.
No. Age Sex BW(g) SP NFT FMI Clinical and pathological diagnosis
Control 1 68 M 1400 None 0 79.7 ALS
2 71 F 1280 Sparse I 78.0 ALS
3 75 M 1090 Sparse I 97.1 Emphysema
4 70 F 1030 None 0 72.4 Schizophrenia
5 80 F 1150 Sparse I 67.8 ALS
6 79 M – Sparse I 90.2 ALS
AD 7 80 F – Frequent V 54.0 AD
8 85 M 1060 Frequent IV 79.5 AD
9 67 F 940 Frequent VI 74.4 AD
10 84 F 1080 Frequent VI 67.6 AD
11 93 F 1150 Frequent VI 74.8 AD
12 77 M 1050 Frequent VI 78.5 AD
SVD 13 80 M 1120 None 0 46.5 SVD
14 70 M 1200 Sparse II 61.6 SVD
15 86 F 940 Sparse III 55.9 SVD
16 76 F 1100 None III 59.9 SVD
17 90 M – Sparse III 47.8 SVD
18 82 M 1050 Sparse I 53.5 SVD
19 82 F 1200 Sparse III 68.5 SVD
AD5Alzheimer’s disease; ALS5 amyotrophic lateral sclerosis; BW5brain weight; FMI5 frontal myelin index; NFT5neurofibrillary tangle;
SP5 senile plaque; SVD5 small vessel disease.
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neurofibrillary tangle stages, and if required, a joint assessment was
scrutinized under a two-headed microscope.
Tinctorial staining and immunohistochemistry
for postmortem human brain samples
Six micrometer-thick paraffin-embedded tissue sections were
cut from the frontal lobes at the level of the olfactory bulbs and
stained for Luxol fast blue. Some sections were also incubated
with specific primary antibodies (listed in Supporting Informa-
tion Table S1) overnight at 48C. Sections were pretreated at
908C for 20 min in Tris-ethylenediamine tetraacetic acid (pH
9.0) for actin, alpha 2, smooth muscle, aorta (ACTA2, also
known as aSMA) and platelet-derived growth factor receptor
alpha (PDGFRA), and some were pretreated at 1218C for 15 min
in 0.01 M citrate buffer (pH 6.0) using an autoclave for BMP2.
This was followed by appropriate biotinylated secondary anti-
body (1:200, Vector Laboratories, Burlingame, CA, USA) and
avidin-biotin-peroxidase complex (1:200, Vector Laboratories),
or polymer Detection System (Histofine Simple Stain MAX PO
MULTI, Nichirei Biosciences, Tokyo, Japan) application.
Between steps, the sections were washed three times for 5 min
with 0.1 M phosphate-buffered saline (PBS, pH 7.4) and visual-
ized using 0.01% diaminobenzidine tetrahydrochloride and
0.003% H2O2 in 50 mM Tris-HCl (pH 7.5).
For triple-immunofluorescence, deparaffinized sections were
incubated with a mixture of primary antibodies overnight at 48C,
followed by Alexa Fluor 488, 594 and 647 conjugated secondary
antibodies (1:200, Invitrogen, Carlsbad, CA, USA) for 2 h at room
temperature.
The images of interest were captured with a microscope (BZ-
X700, Keyence, Osaka, Japan) or a confocal laser-scanning micro-
scope (FV1000, Olympus, Tokyo, Japan).
Assessment of myelin density or
immunohistochemical staining
Myelin density was assessed using immunohistochemistry and
myelin index as previously described (20, 58). Briefly, to deter-
mine the myelin index, the white matter was automatically out-
lined using the wand tool of Image J. If the border between the
cortex and white matter was obscured, the white matter was
manually outlined using the semiautomatic trace tool instead of
the wand tool. The detected range of gray levels within the white
matter, corresponding to the staining intensity, from 0 to 127 (0,
white; 255, black) was divided into four quartiles (the first quar-
tile 0–29, the second 30–62, the third 63–94 and the fourth 95–
127). The percent area for each quartile was calculated. The
median gray level of each quartile (14.5, 46.0, 78.5 and 111.0),
an estimated staining intensity, was then multiplied by percent
area in each quartile and summed up, providing the total myelin
index (Figure 1A).
For immunohistochemical staining, images from 15 to 20 ran-
domly selected ROIs were captured. The images were then con-
verted into 8-bit grayscale, binarized by threshold using the
Triangle Method, and the area above threshold measured using Fiji
and Image J. For quantification of BMP4 immunoreactivity in
PDGFRB- and ACTA2-positive cells, images of PDGFRB or
ACTA2 immunostaining were firstly converted into binarized
images using the Triangle Method and the area above threshold
was selected. The selected area was applied to the same section
with BMP4 immunostaining, and the mean intensity and percent
area of BMP4 in the selected area measured.
The above analyses were performed blinded to the diagnosis by
labeling sections with arbitrary numbers.
Cell culture
Mouse brain vascular pericytes (1200, ScienCell, Carlsbad,
CA, USA) and human brain microvascular endothelial cells
(ACBRI, HBMDC, Cell Systems, Kirkland, WA, USA) were
cultured with pericyte medium (1201, ScienCell) or endothelial
cell growth medium (CC-3156 and CC-4147, Lonza, Basel,
Switzerland) containing 10% fetal bovine serum and 1% peni-
cillin/streptomycin. Endothelial cells were placed on pre-coated
dishes with 3.2% bovine collagen type IV alpha 1 chain
(COL4A1) (A1064401, Invitrogen) in PBS. Oligodendrocyte
precursor cells (OPCs) were isolated from cerebral cortices
from 1- to 2-day-old Sprague Dawley rats as previously
described (8, 30).
Oxygen–glucose deprivation
Upon confluency, pericyte media were replaced with glucose- and
serum-free pericyte media. The following day, culture plates were
placed into a hypoxic culture kit (BIONIX II, Sugiyama-Gen,
Tokyo, Japan) with 5% O2 and 3% CO2, and incubated at 378C for
1, 2 and 3 days.
RT-PCR
After preparing the cell lysate, mRNA was rapidly purified using
the RNeasy Plus Mini Kit (74136, Qiagen, Hilden, Germany) and
subjected to reverse transcriptase-polymerase chain reaction (RT-
PCR) analysis using appropriate primers (listed in Supporting
Information Table S2).
BMP4 and noggin treatment
The media were replaced with new medium with or without
recombinant human BMP4 (1 or 10 ng/ml, 314-BP, R&D systems)
and/or recombinant human noggin (100 ng/ml for proliferation
assay and 500 ng/ml for differentiation assay; 120–10C, Pepro-
Tech, IL, USA). The cells treated with both BMP4 and noggin
were pretreated with only noggin (100 ng/ml for proliferation assay
and 500 ng/ml for differentiation assay) for 2 h.
WST-8 assay
Two days after BMP4 and/or noggin administration, 1% of 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, monosodium salt solution (WST-8, 07553–44,
Nacalai Tesque, Kyoto, Japan) was added to each medium. Then,
the plates were incubated for 1 h at 378C in the incubator. Absorb-
ance at 450 nm and 630 nm were measured using a multi-label
plate reader (2030 ARVO X, PerkinElmer, Waltham, MA, USA).
The results of absorbance at 450 nm were corrected to absorbance
at 630 nm.
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Immunocytochemistry
The cells were fixed with 4% paraformaldehyde/PBS for 15 min at
room temperature, treated with 3% bovine serum albumin for 1 h,
incubated with primary antibodies (listed in Supporting Information
Table S3) overnight at 48C and appropriate secondary antibodies
for 2 h at room temperature. Between steps, the cells were washed
three times for 5 min with PBS.
Tube formation assay
After thawing overnight at 48C, the matrigel (354230, BD Bio-
sciences, Franklin Lakes, NJ, USA) was applied on each well of a
l-slide (81506, Ibidi, Madison, WI, USA) and polymerized for 1 h
at 378C. Then, 50 ll of suspension at a density of 4 3 105 cells/ml
endothelial cells were added to the matrigel surface. After seeding
the cells, the slides were incubated for 24 h at 378C. The number of
tubes was quantified under a microscope.
OPC proliferation assay and differentiation
assay
For the proliferation assay, OPCs were cultured with OPC prolifer-
ation media (Neurobasal medium containing 2 mM glutamine, 1%
penicillin/streptomycin, 10 ng/ml platelet-derived growth factor-
AA, 10 ng/ml basic fibroblast growth factors and 2% B27 supple-
ment). At 30% confluency, the cells were treated with BMP4 and/
or noggin and incubated for 2 days until harvest and analysis by
RT-PCR.
For the differentiation assay, when the cells were 70% confluent,
the OPC proliferation media were replaced with OPC differentia-
tion media (Dulbecco’s-modified Eagle Medium containing 1%
penicillin/streptomycin, 10 ng/ml ciliary neurotrophic factor, 10 ng/
ml triiodothyronine and 2% B27 supplement). Simultaneously,
BMP4 and/or noggin were administered. Four days after treatment,
the cells were analyzed by immunocytochemistry or RT-PCR.
Changes in OPC morphologies were captured using a time-lapse
camera (BZ-X700, Keyence).
Animals and surgical procedure
The protocol for this study was approved by the Institutional Ani-
mal Care and Use Committee, Institute of Laboratory Animals
Graduate School of Medicine, Kyoto University.
Figure 1. Degree of myelin loss and capillary bed density in the frontal
lobes of post-mortem human brain samples. A. A procedure for calcu-
lating myelin index. The median gray level of each quartile (14.5, 46.0,
78.5 and 111.0) is multiplied by percent area in each quartile (29.27%,
69.28%, 1.44% and 0.01%), and summed up to be 37.25 as the mye-
lin index for the representative image of LFB staining. Bar indicates
5 mm. B. Representative images of LFB staining in control, AD, and
SVD cases. Bar indicates 5 mm. C. Representative images of MBP
staining (myelin) in control, AD, and SVD cases. Bar indicates 400 mm.
Black triangles indicate cortex. Asterisks indicate U-fiber. D. Myelin
index calculated from each LFB staining of all three groups. Differences
are significant between any two groups, except between control and
AD: control vs. AD, P50.226; control vs. SVD, **P5 0.001; AD vs.
SVD, *P50.027. E. The percentage of MBP in the WM in all three
groups. Differences are significant between any two groups, except
between AD and SVD: control vs. AD, *P50.027; control vs. SVD,
**P50.001; AD vs. SVD, P50.224. F. Representative images of
COL4A1 staining (basement membrane marker) in control, AD, and
SVD cases. Bar indicates 100 mm. G. The percentage of COL4A1 in
the WM and cortex in all three groups. Differences are not significant
in the WM (P50.095) and cortex (P5 0.095). Vertical bars represent
mean6SEM. Abbreviations are as follows: AD, Alzheimer’s disease;
Cont, control; MBP, myelin basic protein; LFB, Luxol fast blue; SVD,
small vessel disease; WM, white matter.
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Adult C57BL/6J male mice (10–12 weeks old) were subjected
to bilateral common carotid artery stenosis (BCAS) using micro-
coils as previously described (n5 6) (29, 48). Control mice under-
went sham surgery (n5 6). Four weeks after BCAS, mice were
euthanized and their brains analyzed by immunohistochemistry and
western blot (Figure 6A).
In a separate experiment, mice received continuous intracerebro-
ventricular infusion (cICV) 2 days prior to BCAS using brain
infusion kit 3 (0008851, Alzet, Cupertino, CA, USA) and micro-
osmotic pump (1004, Alzet) under stereotaxis. The pumps were
filled with recombinant human noggin (500 ng/day or 1000 ng/
day) in artificial cerebrospinal fluid (ACSF, 3525, Funakoshi,
Tokyo, Japan), or ACSF only, as previously described (42, 43).
Control mice underwent sham surgery (n5 6 for sham control;
n5 6 for BCAS and ACSF; n5 5 for BCAS and noggin 500 ng/
day; n5 6 for BCAS and noggin 1000 ng/day) (Figure 6H).
Immunohistochemistry for mouse brain
Mice were anesthetized and intracardially perfused with cooled
PBS. The brains were quickly frozen using powdered dry ice. Cor-
onal sections (20-lm thick) were cut on a cryostat at 2208C and
collected onto glass slides. As previously described (47), sections
were fixed with 4% paraformaldehyde/PBS for 15 min and incu-
bated with antibodies (listed in Supporting Information Table S4).
Quantitative analyses of glial fibrillary acidic protein (Gfap)-
positive astrocytes, oligodendrocyte transcription factor (Olig2)-
positive oligodendrocyte lineage cells, and myelin basic protein
(Mbp)-positive mature oligodendrocytes were performed in the
bilateral paramedian corpus callosum using Image J.
Western blot
Western blot analysis was performed as previously described (28).
Briefly, the dorsal half of the brain at 0–0.5 mm anterior to bregma
was homogenized in radio-immunoprecipitation assay buffer, fol-
lowed by sonication for 5 min with a 30-s interval and centrifuga-
tion at 14 000 rpm for 5 min at 48C. The supernatant was boiled in
sample buffer (1% (w/v) sodium dodecyl sulfate (SDS), 12.5% (w/
v) glycerol, 0.005% (w/v) bromophenol blue and 2.5% (v/v) 2-
mercaptoethanol in 25 mM Tris-HCl, pH 6.8). Samples were sepa-
rated onto 10% (w/v) gels for SDS-PAGE or 4%–12% (w/v) gels
for NuPAGE (NP032330X, Invitrogen), followed by transfer to
polyvinylidene difluoride membranes (Millipore, Billerica, MA,
USA). The membranes were then incubated overnight at 48C with
primary antibodies (listed in Supporting Information Table S5) fol-
lowed by the appropriate horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h at room temperature. Immunoreactive
bands were detected with chemiluminescence assay kits (02230,
Nacalai Tesque), ECL Western Blotting Substrate (32106, Thermo
Fisher Scientific, Waltham, MA, USA), and Amersham Imager
600 (GE Healthcare, Buckinghamshire, UK).
Statistical analysis
Statistical analysis was performed using the R statistical package
(www.r-project.org). Statistical significance was evaluated using
two-tailed paired Student’s t-test, the Wilcoxon rank-sum test or
one-way ANOVA followed by the Bonferroni post-hoc test. Pear-
son correlation analysis was performed to observe a possible
correlation. For all analyses, the level of statistical significance was
set at **P< 0.01 or *P< 0.05.
RESULTS
Myelin loss in SVD and AD compared with
controls
Luxol fast blue staining (Figure 1B) and MBP immunohistochemi-
cal staining (Figure 1C) represented severe myelin attenuation in
the SVD group. The myelin index was significantly different
between the SVD group and the other two groups as follows: con-
trols (80.9)>AD (71.5)> SVD (56.3) (Figure 1D), indicating that
myelin loss was greatest in the SVD group. Age did not correlate
with myelin index (r520.329, P5 0.170, data not shown). The
percent area of MBP immunoreactivity also decreased in the SVD
group (Figure 1E).
Capillary bed density
Capillary bed density was determined by immunohistochemistry
using antibody specific to COL4A1, a major constituent of the
basement membrane (Figure 1F). Quantitative analysis showed that
the percentage of COL4A1 density was not different in the white
matter or cortex between the three groups (white matter, P5 0.095;
cortex, P5 0.095) (Figure 1G).
Pericyte density in the postmortem human
brain
Pericyte density was assessed by two different markers: ACTA2
and platelet-derived growth factor receptor beta (PDGFRB). The
percentage of ACTA2 and PDGFRB expression, respectively, were
divided by the percentage of COL4A1 stained area to correct for
vascular density.
The ACTA2 immunoreactivity was not different in the white
matter and cortex between the three groups (white matter,
P5 0.123; cortex, P5 0.220) (Figure 2A,B). Conversely, the
percentage of PDGFRB expression was significantly increased in
white matter of the SVD group compared with the other two groups
(Figure 2C,D). There was a significant inverse correlation between
the percentage of PDGFRB/COL4A1 expression in the white mat-
ter and myelin index in all 19 cases combined (r520.568,
*P5 0.013) (Figure 2E).
BMP4 expression in PDGFRB-positive pericytes
of damaged white matter in the postmortem
human brain
BMP4 was strongly expressed in abluminal surface of capillaries
and tunica media of arterioles, and mildly expressed in macro-
phages, and activated astrocytes in the white matter of SVD brains.
Triple immunofluorescence studies revealed abundant BMP4
expression in PDGFRB- and ACTA2-positive pericytes in the
white matter of SVD cases. However, in control or AD brains,
BMP4 expression was weak (Figure 3A).
Similar to the percentage of PDGFRB/COL4A1 expression, the
percentage of BMP4/COL4A1 expression was significantly
increased in the white matter of SVD cases but was not different in
the cortex between the three groups (Figure 3B). BMP4 expression
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negatively correlated with the myelin index (r520.549,
*P5 0.015) (Figure 3C) in all 19 cases combined. Fluorescence
intensity and percentage of BMP4-positive area in PDGFRB- and
ACTA2-positive cells were increased in SVD cases (Figure 3D–G),
suggesting BMP4 expression was increased in pericytes. BMP4
expression was also observed in activated astrocytes and macro-
phages in SVD, but not control or AD, cases (data not shown).
Other TGFB superfamily members (TGFB1,
BMP2, BMP6, BMP7 and BMP9)
Macrophages and activated astrocytes within the vicinity of micro-
infarcts were immunoreactive to all six TGF superfamily members.
BMP2 was highly expressed in the endothelial cells of arterioles,
venules and capillaries, and pericytes of capillaries in all three
groups. BMP7 and TGFB1 were slightly expressed in the tunica
media of arterioles and capillaries. BMP6 and BMP9 were not
expressed in blood vessels (Supporting Information Figure S1).
Oligodendrocyte precursor cells and astrocytes
in the postmortem human brain
PDGFRA-positive OPCs were found in the subventricular zone
(SVZ), and cellular processes of some OPCs were found around
arterioles, venules and capillaries (Figure 3H, Supporting Informa-
tion Figure S2). The number of brain interstitial OPCs was meas-
ured in the SVZ of all cases and found to be increased relative to
white matter attenuation, as previously described (33). However,
when the SVD cases were divided into two groups by the cut-off
point of 0.31 for BMP4/COL4A1, the higher BMP4/COL4A1
group (SVD 2, n5 4) tended to have a smaller number of OPCs
than the lower BMP4/COL4A1 group (SVD 1, n5 3) (Figure 3I).
The GFAP-positive astrocytes were increased in the white matter
of SVD cases (Figure 3J).
BMP4 expression in cultured pericytes under
oxygen–glucose deprivation
To confirm whether BMP4 is increased in pericytes under chronic
hypoperfusion, we analyzed Bmp4 mRNA expression in cultured
pericytes under continuous OGD. The mouse brain microvascular
pericyte cell line expressed both Pdgfrb and Acta2 (Figure 4A).
Bmp4 mRNA expression exhibited a time-dependent increase
under continuous OGD for 3 days (Figure 4B). Pdgfrb, but not
Acta2, mRNA expression increased under OGD (Figure 4C,D).
Expression of each mRNA sample was normalized to
hypoxanthine-guanine phosphoribosyltransferase expression (Hprt)
expression, which did not fluctuate under continuous OGD.
Effects of BMP4 on pericyte proliferation and
Pdgfrb/Acta2 mRNA expression
The WST-8 assay showed that high-dose BMP4 induced pericyte
proliferation (Figure 4E). BMP4 also increased Pdgfrb (Figure 4F)
and Acta2 (Figure 4G) mRNA expression levels.
Effects of BMP4 on endothelial cell
proliferation and tube formation
Endothelial cell proliferation in response to BMP4 treatment was
assessed by immunocytochemistry (Figure 4H) and WST-8 assay
Figure 2. Pericyte density as assessed by ACTA2 and PDGFRB
labeling in the post-mortem human brain samples. A. Representative
images of ACTA2 staining in control, AD, and SVD cases. Insets
show ACTA2-positive pericytes. Bars indicate 100 mm and 10 mm
(insets). B. The percentage of ACTA2 in the WM and cortex in all
three groups. Differences are not significant in the WM (P5 0.123)
and cortex (P50.220). C. Representative images of PDGFRB stain-
ing in control, AD, and SVD cases. Insets show PDGFRB-positive
pericytes. Bars indicate 100 mm and 10 mm (insets). D. The percent-
age of PDGFRB in the WM and cortex in all three groups. Differen-
ces are significant between control and SVD in the WM: control vs.
AD, P5 0.955; control vs. SVD, *P50.046; AD vs. SVD, P50.081.
Differences are not significant in the cortex (P50.464). E. An
inverse correlation between the percentage of PDGFRB and the
myelin index all 19 cases combined (r520.568, *P50.013). Vertical
bars represent mean6SEM. Abbreviations are as follows: AD, Alz-
heimer’s disease; Cont, control; SVD, small vessel disease; WM,
white matter.
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(Figure 4I). Endothelial cell proliferation and tube formation (Fig-
ure 4J,K) were facilitated in a dose-dependent manner by BMP4,
but were blocked by the BMP4 antagonist, noggin.
Effects of BMP4 on oligodendrocyte precursor
cells
In the OPC proliferation assay, treatment of BMP4 converted
OPCs into astrocyte-like cells, with thick and long processes (Fig-
ure 5A and Supporting Information Movie S1). Immunocytochem-
istry showed that BMP4 treatment decreased Pdgfra (OPC marker)
immunoreactivities and increased Gfap (astrocyte maker) (Figure
5B). RT-PCR also showed that BMP4 decreased Pdgfra mRNA
levels, and significantly increased Gfap mRNA levels in a dose-
dependent manner; noggin blocked the conversion (Figure 5C,D).
Treatment with noggin alone increased Pdgfra mRNA levels in
OPCs due to inhibition of endogenous BMP4 (Figure 5C).
The effects of BMP4 on OPCs were also observed in the OPC
differentiation assay. In the differentiation media, primary OPCs
differentiated into mature oligodendrocytes, whereas BMP4 treat-
ment induced astrocyte-like cells (Supporting Information Figure
S3A and Movie S2). BMP4 treatment decreased Mbp
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(oligodendrocyte marker) and increased Gfap in a dose-dependent
manner; noggin also blocked the conversion (Supporting Informa-
tion Figure S3B–D).
Bmp4 expression and effect of noggin in the
mouse brain under chronic hypoperfusion
Adult mice subjected to BCAS and noggin cICV (or ACSF only)
treatment were analyzed by immunohistochemistry and western
blot (Figure 6A,H). The inhibitory effect of noggin on BMP signal-
ing was confirmed by a reduction of phosphorylated Smad immu-
noreactivity (data not shown).
Bmp4 was expressed in the Acta2/Pdgfrb double-positive peri-
cytes in capillaries of 28-day-BCAS mouse brains (Figure 6B).
Western blot showed significantly increased expression of Bmp4
precursor (Figure 6C,D and Supporting Information Figure S4A)
and Pdgfrb (Figure 6E,F and Supporting Information Figure S4B),
but not Acta2 (Figure 6E,G and Supporting Information Figure
S4C) after BCAS, compared with sham controls. The Bmp4 pre-
cursor (41) was detected by both C-terminal (ab39973, Abcam,
Cambridge, UK) and N-terminal (MAB1049, Millipore, and sc-
393329, SantaCruz, Dallas, TX, USA) domain antibodies (data not
shown). The expressions of western blot sample were normalized
to tubulin gamma 1 (Tubg1) expression, which did not fluctuate
under hypoperfusion.
The percent area of Gfap expression increased after BCAS,
which was suppressed by noggin cICV (Figure 6I,J). The percent
area of Olig2 expression was decreased by BCAS, which was ame-
liorated by noggin cICV at a dosage of 1000 ng/day (Figure 6I,K).
Western blot also showed significantly increased Gfap expressions
in the BCAS mice, which was suppressed by noggin cICV (both
500 ng/day and 1000 ng/day) (Figure 6L,M and Supporting Infor-
mation Figure S4D). Olig2 expression was decreased by BCAS,
which was ameliorated by a high dose of noggin cICV (1000 ng/
day) (Figure 6L,N and Supporting Information Figure S4E). Each
band of Gfap and Olig2 was normalized with non-specific band
stained with ponceau S staining (Figure 6L and Supporting
Information Figure S4F). To assess the effect of BMP4 on mature
oligodendrocytes, the percent area of Mbp expression was quanti-
tated. The percent area of Mbp was decreased by BCAS, which
was ameliorated by noggin cICV at a dosage of 1000 ng/day (Fig-
ure 6O,P).
DISCUSSION
We previously reported that myelin loss evolved in parallel with
shrunken oligodendrocytes in SVD compared with AD (20).
Another study revealed that spongiosis, arteriolosclerosis, etat
crible and myelin loss were more severe in the SVD cases than the
AD cases (13), suggesting different etiologies underlie the white
matter attenuation between SVD and AD. In this study, we clarified
one of the causative factors underlying the different aspects of
white matter changes: namely, BMP4 generated from pericytes.
We analyzed expressions of six TGFB superfamily members in the
brains of SVD, AD, and age-matched controls, and found BMP4
was distinctly expressed in pericytes of the white matter. BMP4
expression was significantly upregulated in the SVD group, and
was negatively correlated with myelin density. Consistent with
these findings, long-term OGD in cultured pericytes and in vivo
chronic hypoperfusion induced BMP4 upregulation. Given that
chronic hypoperfusion during late embryonic stages (36) and neo-
natal stages (12) increases BMP4 expression and impairs differen-
tiation of OPCs, chronic hypoperfusion may also upregulate BMP4
in the elderly. Recent evidence suggests that Tgfb upregulation
contributes to cerebrovascular dysfunction in mice (34), which
ascertains CARASIL pathogenesis in humans through hereditary
loss of HtrA1 (18). Therefore, these results suggest upregulation of
the TGFB superfamily members is a shared mechanism in the
pathogenesis of ischemic cerebrovascular disorders, regardless of
whether it is sporadic or hereditary.
Previous studies have shown that Bmps, including Bmp2, 4, 6
and 7, are upregulated in a variety of CNS injury and demyelinating
disease animal models (14, 45). In this study, expression of all six
Figure 3. Pericyte BMP4 expression in damaged white matter in the
post-mortem human brain samples. A. Representative triple-
immunofluorescent images for BMP4, PDGFRB, and ACTA2, and their
merged images in the WM of all three groups. Insets show enlarged
pericytes. Bars indicate 400 mm and 10 mm (insets). B. The percent-
age of BMP4 expression in all three groups. Differences are signifi-
cant between any two groups, except between control and AD in the
WM: control vs. AD, P5 0.804; control vs. SVD, **P5 0.003; AD vs.
SVD, *P50.012. Differences are not significant in the cortex
(P50.659). C. An inverse correlation between the percentage of
BMP4 expression and the myelin index in all 19 cases combined
(r520.549, *P5 0.015). D. The percent area of BMP4 expression in
PDGFRB-positive cells in the WM of all three groups. Differences are
significant between any two groups, except between control and AD:
control vs. AD, P50.593; control vs. SVD, **P50.001; AD vs. SVD,
*P50.011. E. The mean intensity of BMP4 in PDGFRB-positive cells
in the WM of all three groups. Differences are significant between
any two groups: control vs. AD, **P< 0.001; control vs. SVD,
**P< 0.001; AD vs. SVD, *P50.017. F. The percent area of BMP4
expression in ACTA2-positive cells in the WM of all three groups.
Differences are significant between any two groups, except between
control and AD: control vs. AD, P50.079; control vs. SVD,
**P< 0.001; AD vs. SVD, **P< 0.001. G. The mean intensity of
BMP4 in ACTA2-positive cells in the WM of all three groups. Differen-
ces are significant between any two groups: control vs. AD,
**P< 0.001; control vs. SVD, **P< 0.001; AD vs. SVD, *P5 0.018.
H. Representative images of PDGFRA expression in the interstitium
of the SVZ in the cases of control, AD, and SVD of post-mortem
human brain samples. According to expression levels of BMP4
(BMP4-to-COL4A1 ratio), the SVD cases are further classified into
subgroup: a lower BMP-4 expressing group (SVD 1) and a higher one
(SVD 2) with the cut-off ratio of 0.31. Insets show enlarged images of
OPCs. Bars indicate 50 mm and 10 mm (insets). I. The number of
OPCs in all 4 groups. SVD 2 group shows smaller number of OPCs
compared with SVD 1 group. J. Representative images of GFAP
expression in the WM of post-mortem human brain samples. The
WM of SVD shows severe astrogliosis with high GFAP expression.
Bar indicates 50 mm. Vertical bars represent mean6SEM. Abbrevia-
tions are as follows: AD, Alzheimer’s disease; Cont, control; SVD,
small vessel disease; SVZ, subventricular zone; WM, white matter.
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TGFB superfamily members was also observed in macrophages and
activated astrocytes within the vicinity of microinfarcts in the SVD
group. However, in demyelinated but not infarcted areas, of the
SVD group, BMP4 was almost exclusively expressed in pericytes.
The density of PDGFRB-positive pericytes in the white mat-
ter correlated with myelin attenuation. In previous studies,
PDGFRB immunostaining was used to assess microvasculature,
showing a reduction of PDGFRB-positive pericytes and a
Figure 4. Effects of BMP4 expression on cultured endothelial cells
and pericytes. A. Representative images of mouse pericyte cell line.
The cells express Pdgfrb and Acta2, both established pericyte
markers. Bar indicates 50 mm. B–D. Relative mRNA levels of Bmp4
(B), Pdgfrb (C) and Acta2 (D) in cultured pericytes under OGD. Bmp4
mRNA levels show a time-dependent increase with continuous OGD
for 3 days (*P5 0.024 for Day 1 and **P< 0.001 for Days 2 and 3).
Pdgfrb mRNA levels are increased (**P< 0.001 for Days 1, 2 and 3),
but Acta2 mRNA levels are decreased (**P< 0.001 for Days 1, 2 and
3) by OGD. The expression of each mRNA sample is normalized to
Hprt expression, which does not fluctuate under continuous OGD. E.
Relative viability of pericytes as assessed by WST-8 assay. High-dose
BMP4 increases pericyte viability (**P< 0.001 for 50 ng/ml), which is
blocked by noggin (**P5 0.009). F, G. Relative mRNA levels of
Pdgfrb and Acta2 in cultured pericytes after BMP4 administration.
BMP4 increases Pdgfrb mRNA levels in a dose-dependent manner
(**P5 0.001 for 10 ng/ml and **P< 0.001 for 50 ng/ml), which is
blocked by noggin (**P50.009) (F). BMP4 increases Acta2 mRNA
levels (**P< 0.001 for 1, 10 and 50 ng/ml), which is blocked by nog-
gin (**P50.002) (G). H. Representative images of PECAM1-positive
endothelial cells after additions of BMP4 with or without noggin. Bar
indicates 50 mm. I. Relative viability of endothelial cells as assessed
by WST-8 assay. BMP4 increases viability of endothelial cells in a
dose-dependent manner (**P< 0.001 for 1, 10 and 50 ng/ml), which
is blocked by noggin (**P< 0.001). J. Representative images of endo-
thelial cell tube formation after BMP4 additions with or without nog-
gin. Bar indicates 500 lm. K. BMP4 facilitates tube formation of
endothelial cells (**P50.008 for 50 ng/ml), which is blocked by nog-
gin (**P< 0.001). Vertical bars represent mean6SD. Abbreviations
are as follows: ECs, endothelial cells; Gapdh, glyceraldehyde-3-
phosphate dehydrogenase; Hprt, hypoxanthine-guanine phosphoribo-
syltransferase expression; OGD, oxygen–glucose deprivation;
PECAM1, platelet and endothelial cell adhesion molecule 1, also
known as CD31.
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breakdown of the blood-brain barrier in vascular cognitive
impairment and some neurodegenerative diseases, including AD
and ALS (46, 51, 55, 56, 59). However, a recent study showed
increased expression of PDGFRB immunoreactive pericytes in
cerebral microvessels in CADASIL (cerebral autosomal domi-
nant arteriopathy with subcortical infarcts and leukoencephalop-
athy) compared with similar age controls (11). It has also been
suggested that Pdgfrb mRNA is upregulated in pericytes in the
infarcted area (37), and Pdgfrb-positive pericytes migrate into
the peri-infarct area after stroke, contributing to angiogenesis
and vascular remodeling (25). In the current study, Pdgfrb
expression was also upregulated by chronic hypoperfusion in
the BCAS mice. Given that the PDGFRB is important for prolif-
eration and migration of pericytes (55), PDGFRB may be
increased in pericytes at a certain point, as compensation for
hypoperfusion.
Figure 5. Effects of BMP4 on cultured oligodendrocyte precursor
cells. A. Time-lapse images of primary OPCs in proliferation media
with or without BMP4. Insets show enlarged images. Bars indicate 100
lm and 50 lm (insets). B. Representative triple-immunofluorescent
images for Pdgfra and Gfap, and their merged images with DAPI for
nuclear staining. Insets show enlarged images. Bars indicate 50 mm
and mm (insets). C, D. Relative mRNA levels of Pdgfra and Gfap in the
proliferation assay. (C) BMP4 decreases Pdgfra mRNA levels in a dose-
dependent manner (P50.062 for 1 ng/ml and **P< 0.001 for 10 ng/
ml), which is blocked by noggin (**P50.001). Treatment with noggin
alone increases Pdgfra mRNA levels (*P50.015). (D) BMP4 signifi-
cantly increases Gfap mRNA expression in a dose-dependent manner
(**P50.004 for 1 ng/ml and **P< 0.001 for 10 ng/ml), which is
blocked by noggin (**P< 0.001). Vertical bars represent mean6SD.
Abbreviations are as follows: Cont5 control; Gapdh5 glyceraldehyde-3-
phosphate dehydrogenase.
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Unlike PDGFRB, ACTA2 expression was not different between
the three groups. In terms of tumor angiogenesis, Acta2 served as a
mature pericyte marker whereas Pdgfrb served as a marker for pro-
genitor perivascular cells with the ability to differentiate into peri-
cytes and regulate vessel stability and vascular survival (50).
Therefore, the differences in PDGFRB and ACTA2 expression
may be the result of different stages of pericyte maturation;
PDGFRB-positive pericytes in the white matter are immature peri-
cytes during angiogenesis following chronic hypoperfusion, and
PDGFRB-negative/ACTA2-positive pericytes are mature pericytes
in relatively intact white matter. Because BMP4 treatment facili-
tated pericyte proliferation and Pdgfrb mRNA expression, an
increase in PDGFRB-positive pericytes in the SVD group might be
induced by BMP4 in response to chronic hypoperfusion. BMP4
also facilitated proliferation and tube formation of endothelial cells,
which is another key factor for maintenance of vascular integrity.
These results suggest that BMP4 induces inherent compensatory
angiogenesis against chronic hypoperfusion. Despite the putative
compensatory responses, COL4A1-positive vessel density was not
significantly different in SVD compared with AD or disease control
patients in the cerebral cortex and white matter, suggesting that
angiogenesis was not sufficient or compensatory enough to recruit
blood vessels and mitigate cerebral hypoperfusion in SVD patients.
Because time-specific induction of BMP4 and PDGFRB is neces-
sary for successful angiogenesis, long-lasting hypoperfusion in the
aged brain may block appropriate angiogenesis to restore regional
blood flow (52).
With regard to myelination, BMP4 overexpression may not be
preferable. BMP4 treatment has been shown to induce differentia-
tion of oligodendroglial-astroglial progenitor cells into astrocytes
(17, 27). Our results also showed that BMP4 strongly suppressed
maturation of primary OPCs and converted OPCs into astrocytes in
differentiation media. Compared with 1.2- to 2-fold changes in
angiogenesis, the degree of inducing astrogliogenesis (49) and sup-
pressing oligodendrogenesis was exponential. Furthermore, even
when the OPCs were cultured in proliferation media which should
maintain an OPC state, BMP4 treatment decreased Pdgfra mRNA
expression in a dose-dependent manner. This finding was inconsis-
tent with other studies that demonstrated no effect (16, 57) or even
a positive effect (43) of BMP4 on OPC proliferation. However,
recent studies have suggested that the effects of BMP4 on stem cell
proliferation are dose-dependent; low dose BMP4 increases prolif-
eration, but high dose BMP4 decreases proliferation of mesenchy-
mal stem cells (53) or primordial germ cells (31). Considering that
OPC proliferation is also affected by many factors, BMP4 may
have dose-dependent and opposite effects on OPC proliferation.
Consistent with the results of cell culture, the number of OPCs in
SVZ is decreased with higher BMP4 expression of SVD cases with
severe astrogliosis. BCAS mice also showed astrogliosis and hypo-
myelination as shown previously (48). As noggin, a receptor antag-
onist of BMP4, suppressed astrogliogenesis and induced
oligodendrogenesis in vitro, both high and low doses of noggin
cICV decreased the number of astrocytes and high dose of noggin
cICV increased the number of oligodendrocytes.
The close relationship between BMP4 and myelin attenuation is
also supported by recent studies (3, 15, 26, 43). These data strongly
suggest that BMPs are involved in oligovascular pathologies in the
brain. Considering a potential anatomical and functional interaction
between pericytes and OPCs in the capillary of cerebral white mat-
ter (30), the pericyte-induced BMP4 might directly affect OPC line-
age. Because many factors should be expressed in a coordinated
manner after cerebral hypoperfusion, time-specific control of BMP
expression should be further investigated to protect oligovascular
units in ischemic demyelinating diseases.
The main limitation of this study was the lack of clinical and
neuropsychometric information on the postmortem brains used.
This meant that we could not directly relate our pathological find-
ings to antemortem hypoperfusive and cognitive status. In addition,
the lack of comparison of the SVD cases with controls without neu-
rodegenerative pathologies was another limitation considering that
PDGFRB positive pericytes may also degenerate in some neurode-
generative diseases (46, 55, 56, 59). The third limitation is that a
histopathological study using postmortem human brains does not
always uncover the entire cell process that occurs in the ageing
Figure 6. BMP4 expression and effect of noggin in the mouse brain
after chronic hypoperfusion. A. Experimental design of the first trial.
Adult mice subjected to BCAS are analyzed by immunohistochemistry
and western blot. B. Representative triple-immunofluorescent images
for Bmp4, Pdgfrb and Acta2, and their merged images with DAPI for
nuclear staining. Bar indicates 10 mm. C–G. Western blot shows sig-
nificantly increased Bmp4 precursor (C, D) and Pdgfrb (E, F) levels
after BCAS (**P5 0.002 for Bmp4 precursor and **P50.004 for
Pdgfrb), without significant changes in Acta2 levels (P5 0.660) (E, G).
H. Experimental design of the second trial. Adult mice subjected to
BCAS receive noggin (500 ng/day or 1000 ng/day) in ACSF or ACSF
only through cICV 2 days prior to BCAS, are euthanized and their
brains analyzed by immunohistochemistry and western blot. I. Repre-
sentative immunofluorescent images of Gfap and Olig2 with DAPI
(the leftmost images) and their enlarged images (three right images).
Bars indicate 500 mm (left) and 100 mm (right). J. Semiquantitative
analysis of immunofluorescent images shows that BCAS significantly
increases GFAP-positive cells (**P50.004), which is strongly sup-
pressed by noggin cICV (**P< 0.001 for both 500 ng/day and 1000
ng/day). K. Semiquantitative analysis of immunofluorescent images
shows BCAS significantly decreases Olig2-positive cells (**P< 0.001),
which is significantly ameliorated by high dose of noggin cICV
(P50.771 for 500 ng/day and *P50.026 for 1000 ng/day). L–N.
Western blot shows significantly increased Gfap levels after BCAS
(**P< 0.001 for Sham vs. BCAS1ACSF), which is suppressed by
noggin cICV (**P< 0.001 for BCAS1ACSF vs. BCAS1noggin 500
and 1000 ng/day) (L, M). Western blot also shows significantly
decreased Olig2 levels after BCAS (*P5 0.030 for Sham vs.
BCAS1ACSF), which is ameliorated by a high dose of noggin cICV
(P50.698 for BCAS1ACSF vs. BCAS1 noggin 500 ng/day; and
*P50.042 for BCAS1ACSF vs. BCAS1noggin 1000 ng/day) (L, N).
O. Representative images for MBP. Bar indicates 100 mm. P. Semi-
quantitative analysis of immunofluorescent images shows that BCAS
significantly decreases Mbp (**P5 0.001), which is significantly ame-
liorated by high dose of noggin cICV (P5 0.169 for 500 ng/day and
*P50.034 for 1000 ng/day). Vertical bars represent mean6SEM.
Abbreviations are as follows: B, BCAS; cICV, continuous intracerebro-
ventricular infusion; IHC, immunohistochemistry; N500, noggin 500
ng/day; N1000, noggin 1000 ng/day; S, Sham operation; Tubj1, tubulin
gamma 1, also known as gamma tubulin; WB, western blot.
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human brain. Although the process was at least partially modeled
by both cultured pericytes under OGD and mice subjected to
BCAS, future studies should focus on examining dynamic changes
of pericyte disruption and BMP4 values in the disease course of
SVD using neuroimaging and biomarkers.
In summary, our study suggests that during chronic hypoperfu-
sion akin to that in SVD, BMP4 is generated in pericytes predomi-
nantly in the white matter, providing putative compensatory
angiogenesis. However, BMP4 also aggravates white matter dam-
age by inducing astrogliogenesis at the expense of OPC prolifera-
tion and maturation. Based on our observations, we propose a
putative scheme how these cellular processes could occur (Figure
7). This may explain why white matter is particularly vulnerable to
chronic hypoperfusion.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1. Expression of TGFB1, BMP2, BMP6, BMP7, and
BMP9 in white matter. Representative images of TGFB1,
BMP2, BMP6, BMP7, and BMP9 staining in the WM of con-
trol, AD, and SVD, respectively. Insets show TGFB1, BMP2,
BMP6, BMP7, or BMP9-positive activated astrocytes with large
cell bodies (right panels), TGFB1 or BMP7-positive pericytes
(left panels in TGFB1 and BMP7), and BMP2-positive endothe-
lial cells (left panels in BMP2), respectively. Bars indicate 100
mm and 10 mm (insets).
Figure S2. Oligodendrocyte precursor cells in the subventricular
zone. Representative images for PDGFRA-positive cells sur-
rounding arterioles, venules and capillaries in the subventricular
zone. Bars indicate 25 mm.
Figure S3. Effects of BMP4 on oligodendrocyte maturation in
the OPC differentiation assay. (A) Time-lapse images of primary
OPCs in differentiation media with or without BMP4. Insets
show enlarged images. Bars indicate 100 lm and 50 lm
(insets). (B) Representative triple-immunofluorescent images for
Mbp and Gfap, and their merged images with DAPI for nuclear
staining. Insets show enlarged images. Bars indicate 100 mm
and 15 mm (insets). (C, D) Relative mRNA levels of Mbp and
Gfap in the differentiation assay. Mbp mRNA levels decrease in
differentiation media containing BMP4 (**P< 0.001 for 1 and
10 ng/ml) in a dose-dependent manner; the effect of BMP4 is
reversed by noggin (**P< 0.001). Treatment with noggin alone
increases Mbp (**P< 0.001) (C). BMP4 significantly increases
Gfap mRNA expression (**P< 0.001 for 1 and 10 ng/ml) in a
dose-dependent manner; the effect of BMP4 is canceled out by
noggin (**P< 0.001) (D). Vertical bars represent mean6 SD.
Abbreviation is as follow: Cont, control; Gapdh,
glyceraldehyde-3-phosphate dehydrogenase.
Figure S4. Original gel pictures for western blots. The figure
shows uncropped western blots displayed in Fig. 6C. (A) Bmp4
precursor and pro-Bmp4 expressions are increased in BCAS
mice compared with sham controls. Pdgfrb (B), but not Acta2
(C), expression is increased in BCAS mice compared with sham
controls. Each band of Bmp4, Pdgfrb, and Acta2 is normalized
to Tubg1. (D) Gfap expressions are increased in BCAS mice
compared with sham controls, which are suppressed by noggin
cICV (500 ng/day and 1000 ng/day). (E) Olig2 expressions are
decreased in BCAS mice compared with sham controls, which
are ameliorated by a high dose of noggin cICV (1000 ng/day).
(F) Each band of Gfap and Olig2 is normalized to the band at
45 kDa stained with ponceau S. Asterisks show unknown bands.
Abbreviations are as follows: B, BCAS; N500, Noggin 500 ng/
day; N1000, Noggin 1000 ng/day; S, Sham operation.
Table S1. Primary antibodies used for immunohistochemistry of
human brain tissue.
Table S2. Primers used for RT-PCR.
Table S3. Primary antibodies used for immunocytochemistry.
Table S4. Primary antibodies used for immunohistochemistry of
mouse brain tissue.
Table S5. Primary antibodies used for western blot.
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